Published Research > EAJ Ryan, EA Claessens, S Blanco Mejia. The effect of DHEA supplementation on pregnancy rates in women with diminished ovarian reserve (DOR) undergoing IVF treatment. Canadian Fertility and Andrology Society (CFAS) Annual Meeting. September 14th, 2017.


22 Sep 2017

INTRODUCTION: DHEA is an androgen precursor, and it is believed that intraovarianandrogen levels can positively influence ovarian follicular growth (recruitment of pre antral resting follicles 0.2-0.4 mm into the 3-5 mm range, when FSH receptors are acquired), which might lead to improvement on oocyte recruitment. The exact mechanism is not well known, but likely involves insulin like growth factor1increased sensitivity. Some trials have found that the use of supplemental DHEA in women with poor ovarian reserve improves embryo quality(2), implantation rate(3), pregnancy rate(3-8) and areduced pregnancy loss rate(4,11,12).  However, others have found no beneficial effect when compared to  standard treatment(2,12-16). Therefore, its recommendation is still controversial. Our objective is to report our clinic’s pregnancy rate per embryo transfer (PR/ET), clinical pregnancy rate per ET (CPR/ET) and live birth rate (LBR) in women with DOR undergoing IVF treatment with DHEA supplementation.

MATERIALS AND METHODS: In a retrospective study (February 2006-February 2017), we collected information on DHEA-supplemented IVF cycles in women with DOR who had failed to get pregnant on oral  (femara) or injectable fertility medication (COS with IUI). IVF cycles were D3 transfers as all patients had DOR and if left for D5 transfer, they might not have had any embryos  to transfer based on our own experience. We excluded cycles in women ≥44 years old, frozen , and donor cycles. We divided the cycles by age groups: <35yo, 35-39yo, and 40-≤43yo. PR/ET included chemical pregnancies. CPR/ET was defined as an intra uterine pregnancy on ultrasound at 4 weeks post ET. Statistical analyses were performed using STATA version 11.1. 

 

RESULTS: A total of 176 DHEA-supplemented IVF cycles were included, 28 cycles in women <35yo, 69 cycles in women 35-39yo, and 79 cycles in women 40-≤43yo. Average number of embryos transfer red was 3.1 +/-  1.4 (SD). For the three different age groups, the cancellation rate was 17.9% (n=5), 20.3% (n=14), and 26.6% (n=21). Even though the PR/ET was not statistically significant amongst the age groups, 39.1% (n=9), 50.9% (n=28), and 31.0% (n=18), p=0.10, we did see a higher PR/ET in the 35-39yo group. The CPR/ET was 26.1% (n=6), 47.3% (n=26), and 29.3% (n=17), p=0.08. The LBR/ET was 21.7% (n=5), 36.4% (n=20), 20.7% (n=12), p=0.14. From the 49 clinical pregnancies, 13 were multiple pregnancies (26.5%), and 36 were single pregnancies (73.5%).

 

CONCLUSION: The use of DHEA supplementation in our 11-year practice experience in women with DOR undergoing IVF treatment had no statistical significance on PR/ET, CPR/ET and LBR between this notoriously poor prognosis groups. Note has to be made of the very poor prognosis of women under 35yrs with D.O.R. No doubt some of this group likely had fragile X syndrome or more likely gene abnormalities on other autosomes as has been  published over the most recent years(17-20). Our under 35yrs women with DOR had basically the same results as our over 40 yrsgroup.  However, the LBR/ET was higher in our clinic than in the reported CARTR Plus 2015 registry for women with  DOR (35-39yo [30%], and >40yo [10%]).  However, our  clinical pregnancy rate for multiple pregnancy  (26.5%) is more than double  of the rate  reported in CARTR Plus, 2015 (12.2%), therefore we will be using a one single embryo transfer even in women with DOR age over 38yrs  to decrease our multiple pregnancy rate.Overall, the use of DHEA in women with DOR undergoing IVF treatment should not be dismissed and should be investigated in randomized well controlled trials. 

 

REFERENCES:

 

1.CassonPR, Lindsay MS, PisarskaMD, Carson SA, Buster JE. Dehydroepiandrosteronesupplementation augments ovarian stimulation in poor responders: a case series. Human reproduction. 2000 Oct;15(10):2129-32. PubMed PMID: 11006185.
2.Barad D, GleicherN. Effect of dehydroepiandrosteroneon oocyte and embryo yields, embryo grade and cell number in IVF. Human reproduction. 2006 Nov;21(11):2845-9. PubMed PMID: 16997936.
3.Xu B, Li Z, Yue J, JinL, Li Y, Ai J, et al. Effect of dehydroepiandrosteroneadministration in patients with poor ovarian response according to the Bologna criteria. PloSone. 2014;9(6):e99858. PubMed PMID: 24932478. PubmedCentral PMCID: 4059703.
4.JirgePR, ChouguleSM, GavaliVG, BhomkarDA. Impact of dehydroepiandrosteroneon clinical outcome in poor responders: A pilot study in women undergoing in vitro fertilization, using bologna criteria. Journal of human reproductive sciences. 2014 Jul;7(3):175-80. PubMed PMID: 25395742. PubmedCentral PMCID: 4229792.
5.KotbMM, Hassan AM, AwadAllahAM. Does dehydroepiandrosteroneimprove pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. European journal of obstetrics, gynecology, and reproductive biology. 2016 May;200:11-5. PubMed PMID: 26963897.
6.GleicherN, WeghoferA, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosteronesupplementation. Reproductive biomedicine online. 2010 Sep;21(3):360-5. PubMed PMID: 20638339.
7.Mamas L, Mamas E. Dehydroepiandrosteronesupplementation in assisted reproduction: rationale and results. Current opinion in obstetrics & gynecology. 2009 Aug;21(4):306-8. PubMed PMID: 19610174.
8.Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertility and sterility. 2009 Feb;91(2):644-6. PubMed PMID: 18321501.
9.SonmezerM, OzmenB, CilAP, OzkavukcuS, TasciT, OlmusH, et al. Dehydroepiandrosteronesupplementation improves ovarian response and cycle outcome in poor responders. Reproductive biomedicine online. 2009 Oct;19(4):508-13. PubMed PMID: 19909591.
10.Barad D, Brill H, GleicherN. Update on the use of dehydroepiandrosteronesupplementation among women with diminished ovarian function. Journal of assisted reproduction and genetics. 2007 Dec;24(12):629-34. PubMed PMID: 18071895. PubmedCentral PMCID: 3454995.
11.GleicherN, Ryan E, WeghoferA, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone(DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive biology and endocrinology : RB&E. 2009 Oct 07;7:108. PubMed PMID: 19811650. PubmedCentral PMCID: 2764711.
12.TartagniM, CicinelliMV, BaldiniD, TartagniMV, AlrasheedH, DeSalviaMA, et al. Dehydroepiandrosteronedecreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reproductive biology and endocrinology : RB&E. 2015 Mar 09;13:18. PubMed PMID: 25884390. PubmedCentral PMCID: 4355976.
13.Kara M, Aydin T, AranT, TurktekinN, OzdemirB. Does dehydroepiandrosteronesupplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? European journal of obstetrics, gynecology, and reproductive biology. 2014 Feb;173:63-5. PubMed PMID: 24331115.
14.Yeung TW, Chai J, Li RH, Lee VC, Ho PC, Ng EH. A randomized, controlled, pilot trial on the effect of dehydroepiandrosteroneon ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertility and sterility. 2014 Jul;102(1):108-15 e1. PubMed PMID: 24796766.
15.Vlahos N, PapaloukaM, TriantafyllidouO, Vlachos A, VakasP, GrimbizisG, et al. Dehydroepiandrosteroneadministration before IVF in poor responders: a prospective cohort study. Reproductive biomedicine online. 2015 Feb;30(2):191-6. PubMed PMID: 25498594.
16.BormanE, Check JH, Wilson C, Cohen R. No evidence to support the concept that low serum dehydroepiandrosterone(DHEA) sulfate (S) levels are associated with less oocyte production or lower pregnancy rates. Fertility and sterility.94(4):S161.
17.VagniniLD, RenziA, Oliveira-PelegrinGR, CanasMdoC, Petersen CG, MauriAL, Oliveira JB, BaruffiRL, CavagnaM, Franco Junior JG. The TP73 gene polymorphism (rs4648551, A>G) is associated with diminished ovarian reserve. PloSone 2015;10:e0120048.
18.Christin-MaitreS, TachdjianG. Genome-wide association study and premature ovarian failure. Annalesd'endocrinologie. 2010 May;71(3):218-21.
19.McGuire MM, Bowden W, Engel NJ, Ahn HW, KovanciE, RajkovicA. Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletionsassociated with premature ovarian failure. FertilSteril. 2011 Apr;95(5):1595-600.
20.Rossetti R, Ferrari I, BonomiM, PersaniL. Genetics of primary ovarian insufficiency. Clinical genetics 2017;91:183-198.